Kornimate/medical-research-clean huggingface dataset:
influence of prior infection with covid-19 on occurrence of influenza-like illness or acute respiratory infection

Conditions: Influenza, Human; SARS Virus; COVID-19; Espiratory Tract Infections

Summary: background: each belgian winter season is characterized by a wave of influenza like and respiratory symptoms. especially, the elderly people are more vulnerable to be infected by influenza, but also rsv. the recent covid-19 pandemic and eventually a next wave, will increase the prevalence of influenza like and respiratory symptoms. method: a multicentre non-commercial cohort study will be conducted in nursing home staff and residents during the winter season 2020-2021. objectives: primary objective is the difference in incidence of influenza like and respiratory symptoms between cases (cases have evidence of past infection with sars-cov-2, referred to as covid +) and controls (controls have no evidence of previous infection and are referred to as covid -). the primary outcome analysis as well as the secondary outcome analyses will use two strata: nursing home staff and nursing home residents. the secondary objectives are the difference in incidence of covid-19, influenza, rsv infections confirmed by pcr between cases and controls, to define a correlate of protection in the covid + group against re-infection with sars-cov-2 based on the study of the pre-existing antibody profile (antigen specificity, antibody type and antibody level) at the time of re-exposure. a multiplex assay will be used to assess the antibody profile. finally, to study the covid-19 disease severity (7 point who ordinal scale, this includes a.o. hospitalisation, mechanical ventilation need and icu admission, mortality) based on the presence/absence of pre-existing antibodies and the pre-existing antibody profile. for other respiratory infections we will study the need for hospitalization and mortality.


Eligibility criteria:
inclusion criteria: * being a staff member or resident from te participating nursing homes * the subject should be aged 18 years or older, have a belgian national number and be insured by a belgian sickness fund. * all subjects that are cognitively capable to give consent themselves to participate in the study. exclusion criteria: * insufficient knowledge of the dutch or french language. * residents with a previous diagnosis of dementia having a mini-mental state examination (mmse) below 18/30. * participants which life-expectancy is less than the time of the study. * staff members not expected to continue working at the nursing home during the winter season. * participants for whom veins are not accessible for simple periphery blood puncture.
standarization for stappler application during sleeve gastrectomy

Conditions: Obesity

Summary: sleev gastrectomy is a procedure performed for permanent treatment of obesity. for the procedure, cutting of the stomach is performed with differents long of stapplers. the aim of the study is to determine wich long of stappler is applicable in any stage of the procedure ans the variation expected.

after permormed laparoscopic sleeve gastrectomy the stonach retrieved for pathology study will be messured in three ponts: antrum, body and fundus. in each point medition of the two walls and any wall (anterior and posterior) will be messurd. those data will be stariscally analized to perform a applicable guidelines for stapller selection.

Eligibility criteria:
inclusion criteria: * every laparoscopic sleeve gastrectomy * between 18 y.o. and 70 y.o. * no previous gastric operation exclusion criteria: * under 18 y.o. or over 70 y.o. previous gastric surgery

Keywords: stapplers- obesity- stomach
prevalence assessment and characterization of psychological disorders associated with hypobetalipoproteinemia

Conditions: Hypobetalipoproteinemia

Summary: familial hypobetalipoproteinemia (fhbl, omim # 1707730) is a genetic disorder heterozygotic of ldl-c metabolism. clinical manifestation range from asymptomatic patients to metabolic (fatty liver, diabetes) or psychiatric disorders still unrecognized. hypopsy research, aims to evaluate prevalence of hypobetalipoproteinemia, and to characterize specific related psychiatric disorders.

familial hypobetalipoproteinemia (fhbl, omim # 1707730) is a genetic disorder heterozygotic of ldl-c metabolism (low density lipoprotein - cholesterol) whose incidence is measured from 1: 500 to 1: 1000. these heterozygous individuals may be asymptomatic or present some clinical (fatty liver, diabetes) or psychiatric manifestations still unrecognized. moreover, these individuals have mostly a longevity syndrome and cardiovascular protection. the fhbl is often due to mutations of the apob (apolipoprotein b), major component of ldl, vldl (very low density lipoprotein) and chylomicrons, and in some cases, loss-of-function mutations of the serine protease pcsk9, endogenous inhibitor of the ldl receptor. hypopsy research, aims to evaluate, in a population with psychiatric disorders, the prevalence of hypobetalipoproteinemia, and to characterize specific related psychiatric disorders.

Eligibility criteria:
inclusion criteria: * patients admitted in mental disorders unit in nantes university hospital exclusion criteria: * minor patient
a short-term appetite suppression trial using appethyl™: the pizza

Conditions: Overweight; Obesity

Summary: the purpose of the study is to determine whether appethyl™, made from spinach, will reduce appetite and hunger given on the same day of testing.

four hours after breakfast a small amount of liquid to drink will be given to a participant that will contain either the appethyl™ or placebo. participants will be given a lunch of about 750 calories and 40% fat prepared by the metabolic kitchen and be asked to eat all of it. participants will have food choice testing performed 4 hours after starting their lunch meal. this will be done in two ways. participants will be given a list of two foods that are made of carbohydrate like bread and pretzels and be asked which is most preferred. participants will also be given a list of foods that differ in the amounts of fat, carbohydrate and protein that they contain and will be asked to mark the ones that appeal to them. participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. participants are not expected to eat all of the pizza.

Eligibility criteria:
inclusion criteria: * you are a male or female aged 18 to 65 years. * you have a bmi (a number calculated from your height and weight) between 25-35 kg/m2, inclusive. * your waist circumference is over 35 inches. exclusion criteria: * you have been on a diet for weight loss in the last 2 months. * you are being treated for blood pressure, diabetes, heart disease, rheumatoid arthritis, or blood vessel disease. * you have a psychotic illness. * you have other chronic diseases like an inflammatory bowel disease such as crohn's disease or ulcerative colitis. * you have a dysfunction of your gastrointestinal tract. * you have food allergies. * you have rheumatoid arthritis with inflammation. * you have chronic constipation. * you are taking any products to lose weight such as medication for obesity or non-prescription medications for weight loss.
comparative study on the efficacy and safety of ondansetron oral membrane for the prevention of vomiting during moderate hypoemetic chemotherapy

Conditions: To Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy

Summary: children aged 4-15 years scheduled to receive moderate or low emetic chemotherapy were randomly assigned to arm-a (ondansetron mouth soluble film) or arm-b (ondansetron tablet). children recruited to arm-a received ondansetron mouth soluble film plus dexamethasone. children recruited to arm-b received ondansetron tablet plus dexamethasone. ondansetron and dexamethasone were given continuously until 48hours after completion of chemotherapy. the primary end point of the study was to determine the proportion of patients who achieved a cr, defined as no vomiting, no retching, and no use of rescue medication, the proportion of patients who achieved a cr during the acute phase (0-24 hours) after administration of the last dose of chemotherapy. secondary end points were the proportion of patients who achieved a cr during the 24-120 hours (delayed phase) and overall after administration of the last dose of chemotherapy


Eligibility criteria:
inclusion criteria: * patients aged 4 to 15 years who have been diagnosed with malignant tumor through pathological examination and need to receive chemotherapy, gender is not limited; * receive moderate and low grade emetic chemotherapy; * patients with a score greater than 60 or higher have a life expectancy greater than 3 months; * the patients were enrolled voluntarily, and the family members signed the informed consent, and the family members had good compliance and accurately recorded the vomiting diary. exclusion criteria: * children allergic to 5ht3 antagonists; * active infection; * abnormal bone marrow function (absolute neutrophil count \<1000/mm3 platelet count \<100000/mm3); * abnormal renal function in serum creatinine beyond the upper age limit of normal (uln); * abnormal liver function of serum aspartate aminotransferase and alanine aminotransferase, age and serum bilirubin are 1.5 times that of uln; * vomiting 24 hours before chemotherapy begins; * start systemic corticosteroid therapy within 72 hours prior to study drug use, or plan to receive corticosteroids as part of a chemotherapy regimen; * patients with benzodiazepines or opioids

Keywords: ondansetron mouth soluble film ondansetron tablet effectiveness security cinv
subscapularis repair in reverse shoulder arthroplasty

Conditions: Rotator Cuff Tear Arthropathy

Summary: this study will evaluate the subscapularis repair versus non-repair during a reverse shoulder arthroplasty (rsa).

the primary objective of this study is to evaluate pain and function in patients undergoing rsa with or without subscapularis repair. this primary outcome will be measured by analysis of constant scores at two years post-operative. secondary objectives are to evaluate pain, function and imaging, between the two groups at each applicable time point.

Eligibility criteria:
inclusion criteria: 1. patient is scheduled to undergo a reverse shoulder arthroplasty procedure using the arthrex reverstm system. 2. patient voluntarily consents to participate in the study and has the mental and physical ability to participate in the study, fill out subjective questionnaires, return for follow-up visits, and comply with prescribed post-operative physical therapy. 3. patient meets fda cleared indications for reverse shoulder arthroplasty 4. patient is between 18-100 years old 5. patient agrees to also be enrolled in the arthrex total shoulder registry study 6. patient has a standard of care pre-operative ct taken within 6 months that has been submitted for arthrex virtual implant positioning tm (vip) planning exclusion criteria: 1. patient has a history of ipsilateral shoulder arthroplasty 2. a history of shoulder septic arthritis 3. a full thickness subscapularis tear 4. an acute or malunited proximal humeral fracture 5. chronic locked dislocation 6. rheumatoid arthritis 7. tumors 8. axillary nerve damage 9. non-functioning deltoid muscle 10. glenoid vault deficiency precluding baseplate fixation 11. infection and neuropathic joints 12. known or suspected non-compliance, drug or alcohol abuse 13. patients incapable of judgement or under tutelage 14. inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, contraindication for imaging etc. 15. the subject is related to investigator as family members, employees, or other dependent persons 16. any prior open anterior shoulder surgery that included takedown of the subscapularis tendon or violation of the subscapularis tendon (i.e. latarjet, bristow)
health literacy, stress and quality of life in heart failure patients

Conditions: Heart Failure

Summary: heart failure is showing a trend of affecting younger individuals. middle-aged heart failure patients are often the economic backbone of their families. studies have also pointed out that approximately 38.5% of patients with acute heart failure are re-hospitalized within a year of discharge due to worsening symptoms. patients with lower health literacy tend to have poorer health outcomes and higher re-hospitalization rates. however, there is limited research on the life and work stress, health literacy, and quality of life of middle-aged heart failure patients. therefore, this study aims to use machine learning to analyze and predict the correlations between health literacy, stress, and quality of life in heart failure patients. this research is a cross-sectional correlational study, adopting convenience sampling. the study subjects are cardiology patients aged 18-65 diagnosed with heart failure classified as nyha ii or above by specialists at a regional teaching hospital in northern taiwan. data collection took place in the outpatient and inpatient departments of cardiology and cardiothoracic surgery. structured questionnaires were used for one-on-one interviews, including basic demographic information of heart failure patients, the chinese version of the european health literacy survey questionnaire (hls-eu-q47), the chinese version of the brief resilience scale (brs), the perceived stress scale (pss), and the minnesota living with heart failure questionnaire (mlhfq). data will be recorded using excel, and statistical analysis will be conducted using spss version 22. descriptive statistics such as percentages, means, and standard deviations will be used to describe the demographic and variable distributions. independent t-tests, anova, and pearson correlation coefficient will be used to analyze correlations between variables. machine learning will be employed to analyze and predict quality of life factors in heart failure patients. it is hoped that the results of this study can provide references for nursing practice, help with clinical patient assessment, and improve the quality of care for patients.


Eligibility criteria:
inclusion criteria: * the study subjects are cardiology patients aged 18-65 diagnosed with heart failure classified as nyha ii or above by specialists at a regional teaching hospital in northern taiwan exclusion criteria: * 1.severe mental disease.2. terminal stage of other disease such as cancer.

Keywords: machine learning, health literacy, stress, quality of life.
a safety study of vimovo in adolescents with juvenile idiopathic arthritis (jia)

Conditions: Juvenile Idiopathic Arthritis (JIA)

Summary: a 6-month study of the safety of vimovo in adolescents aged 12 to 16 years with jia.

study with completed results acquired from horizon in 2024.

Eligibility criteria:
inclusion criteria: * parent or legal guardian is able to provide written informed consent and patient is able to provide written assent if appropriate. * male and female adolescents aged 12 to 16 years at the time of enrollment. * diagnosed with jia, including all the international league of associations for rheumatology jia subtypes: oligoarthritis, polyarthritis (both rheumatoid factor \[rf\]+ and rf-), psoriatic arthritis, enthesitis-related arthritis, undifferentiated arthritis, and systemic arthritis. * based upon investigator judgment, it is determined appropriate for the patient to undergo 6 months of continuous treatment with vimovo. * body weight \> 31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass index for age. exclusion criteria: * in systemic jia patients, presence of systemic features (ie, fever, rheumatoid rash, serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to start of study drug. * currently taking (ie, within 4 weeks prior to start of drug) naproxen \> 20 mg/kg/day or \> 1000 mg total daily dose. * hemoglobin ≤ 8.5 g/dl. * individuals who have cardiovascular or cerebrovascular disease, based on history or risk factors. * any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other medical conditions indicated by medical/surgical history, physical, or laboratory examination that might put the patient at greater risk during the study.
safety and tolerability study with vy-htt01, in adults with early manifesting huntington's disease

Conditions: Huntington Disease

Summary: this is the first clinical study of vy-htt01, a gene therapy for early-stage huntington's disease (hd) patients. the primary goal of this trial is to evaluate the safety and tolerability of vy-htt01. this study is a first in human study, phase 1b, open-label, randomized, multicenter, dose escalation study with a delayed treatment control arm.

this dose escalation trial will evaluate the safety and tolerability of 4 single dose levels of vy-htt01. the maximum duration that a subject randomized to treatment may be involved in the study is up to 15 months. delayed treatment subjects will be followed for a minimum of 6 months as a control before moving up into the treatment arm in the next cohort. the maximum duration that a delayed treatment subject may be involved in the study is up to 24 months. subjects who participate in this study will be asked to enroll in a long-term observation study.

Eligibility criteria:
inclusion criteria: * must be at least 18 years old. * have cagn repeat \>39. * have diagnostic confidence score of 4 based on motor, cognitive, or behavioral symptoms. * have a tfc score of 13 to 11. * have stable dosing of neurological and psychiatric medications. * capable of giving informed consent. * able to comply with all procedures and study visits. exclusion criteria: * have any significant structural or degenerative neurologic disease other than hd. * have any chronic disability, significant systemic illness and/or, unstable medical condition, or clinical findings noted. * have primary or secondary immune-compromise due to infections or medical conditions or chronic therapies. * have contraindications to lumbar puncture or increased risks of bleeding upon surgery. * started or changed dose of a concomitant cns medication within 30 days. * had prior neurosurgical procedures that could complicate the study procedures. * have used any investigational therapies within 30 days prior to screening, oligonucleotide therapies within 9 months prior to baseline, or any prior gene therapy. * male or female with reproductive capacity and is unwilling to use highly effective contraception for 12 months after surgery. * have contraindications to mri such as claustrophobia, embedded metal in the body, or known allergy or intolerance to contrast agents.
the relationship between the tumor markers and interstitial lung disease

Conditions: the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients

Summary: the serum levels of carcinoembryonic antigen (cea), carbohydrate antigen 19-9 (ca19-9), ca125 are often increased in interstitial lung disease patients. this study was undertaken to investigate the source of these serum tumor markers.

the serum levels of carcinoembryonic antigen (cea), carbohydrate antigen 19-9 (ca19-9), ca125 are often increased in interstitial lung disease patients. this study was undertaken to investigate the source of these serum tumor markers.we hypothesis that these tumor markers are released from the lung. the broncholveolr lvge fluid levels of carcinoembryonic antigen (cea), carbohydrate antigen 19-9 (ca19-9), ca125 were measured in the interstitial lung disease patients before lung transplantation. the immunohistochemical test was performed in the specimen lung after lung transplantation.

Eligibility criteria:
inclusion criteria 1.interstitial lung disease patients for lung transplantation - exclusion criteria: 1. tumor 2. interstitial lung disease patients could not be performed by lung transplantation

Keywords: carcinoembryonic antigen carbohydrate antigen 19-9 carbohydrate antigen 125
italian registry of pneumonia in immunocompromised patients (argonaut)

Conditions: Community Acquired Pneumonia (CAP)

Summary: this multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for community-acquired pneumonia (cap); conducting biochemical, microbiological and genetic analysis on collected samples.

primary endpoint: collection of in- hospitalisation mortality for all causes in immunocompromised patients with cap enrolled. secondary endpoints: collection of data on admission and during hospitalisation to evaluate clinical response to empirical treatments (including antibiotic therapy) related to severity of disease and microbiological etiology. prevalence of cardiovascular events and all-cause mortality during hospitalization or after discharge. biochemical, microbiological and genetic analysis on collected samples.

Eligibility criteria:
inclusion criteria: hospitalized patients with a confirmed diagnosis of community-acquired pneumonia (cap) characterized by at least one of the following risk factors for immunosuppression: * aids, * aplastic anemia; * asplenia; * hematologic malignancy (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma); * chemotherapy within the last 3 months; * neutropenia defined as a white blood cell count less than 500/dl on a complete blood count; * use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-tnf α), prescribed within the last 6 months before hospital admission; * solid organ transplant; * bone marrow transplant; * chronic oral steroid use (\>10 mg/day prednisone or equivalent ≥3 months before accessing the ed, or cumulative dose \> 600 mg prednisone); * use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \> 600 mg prednisone; * active malignancy; * malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy); * lung malignancy with neutropenia/chemotherapy; * other solid malignancy with neutropenia/chemotherapy; * other immunodeficiency (including congenital/genetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy); * primary immunodeficiency. exclusion criteria: * none

Keywords: cap immunosuppressed immunocompromised pneumonia community-acquired pneumonia;
a survey of the indications for esophagogastroduodenoscopy (egd) in children's hospital of fudan university

Conditions: Digestive System Abnormalities

Summary: esophagogastroduodenoscopy (egd) become more and more common in diagnosing gastroenterology diseases. the investigators want to find which symptoms can support for positive endoscopic findings.

esophagogastroduodenoscopy (egd) become more and more common in diagnosing gastroenterology diseases. and there are indications for egd. here, investigators want to find which symptoms can strongly support for positive endoscopy findings. so, investigators design the study to record the symptoms in detail and diagnosis, and then analysis symptoms and the rate of endoscopic findings.

Eligibility criteria:
inclusion criteria: * all of the patients need esophagogastroduodenoscopic procedures exclusion criteria: * none

Keywords: esophagogastroduodenoscopy paediatric